Pulmonary Arterial Hypertension — Group 1: What the Primary Care Nurse Practitioner Needs to Know
April 22, 2021 1:00pm – 2:00pm (ET) Online
CE: 1.25 contact hours (CH) of continuing education (CE)
0.5 of which may be applied toward pharmacology.
Register now for this free, live webinar, presented by the American Association of Nurse Practitioners® (AANP), for an in-depth look at pulmonary arterial hypertension. Expert nurse practitioner (NP) faculty will describe the disease pathology and provide you with the tools you need to identify symptoms and evidence-based measures to ensure accurate diagnosis and management of the disease. You'll also gain strategies to identify when patients with pulmonary arterial hypertension should be referred to Pulmonary Hypertension Care Centers.
-
Webinar Details
Pulmonary Arterial Hypertension — Group 1: What the Primary Care Nurse Practitioner Needs to Know
When: April 22, 2021, 1-2 p.m. ET (12-1 p.m. CT).
Where: Online via the AANP CE Center.
Cost: Free.
CE credit: This activity is approved for 1.25 contact hour(s) of CE, which includes 0.5 hour(s) of pharmacology, by the American Association of Nurse Practitioners. Activity ID# 21034829. This activity was planned in accordance with AANP Accreditation Standards and Policies.
About the Webinar
Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension (PH), which generally refers to high blood pressure of the arteries of the lungs and may be caused by a variety of conditions. While considered an uncommon condition, if PAH is not treated early, it is associated with worsening symptoms, significant morbidity and a five-year survival rate of approximately 40% to 60%. Major challenges in the care of patients with PAH include delayed diagnosis, delayed initiation of appropriate treatment, delayed referral to PAH specialty centers and underutilization of evidence-based treatment recommendations.
In this educational webinar, you can listen to two expert PAH nurse practitioners (NPs) as they explain why NPs in primary care have such a crucial role in the management of patients with this complex disease.
This CE activity is supported by an educational grant from Actelion Pharmaceuticals, US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Webinar Objectives
- Describe the disease pathology associated with Group 1 PAH.
- Identify symptoms associated with PAH.
- List evidence-based measures used to establish a diagnosis of PAH.
- Identify when patients with PAH should be referred to PH Care Centers.
- Describe current evidence-based strategies used to manage PAH.
-
Speakers
Webinar Faculty
Martha Kingman, FNP, DNP
Martha Kingman, is a family nurse practitioner (FNP) who has been working in the Pulmonary Hypertension Program, a comprehensive care center, at the University of Texas Southwestern Medical Center at Dallas since 2000. She earned a Doctorate in Nursing Practice (DNP) from Texas Christian University in 2011. Dr. Kingman serves on various PH advisory boards and steering committees; has spoken at local, national and international conferences; and is a sub-investigator in several ongoing PH clinical trials. She is an active member of the PH Professional Network and is past Chair of the symposium planning committee. Dr. Kingman has numerous PH publications and served on the Editorial Board of the Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association. Her main area of interest involves the management of prostacyclin therapies.
Susanne E. McDevitt, MSN, ACNP-BC
Susanne E. McDevitt is an acute care nurse practitioner (ACNP) in the Pulmonary Hypertension Program, Division of Cardiovascular Medicine, at the University of Michigan Health System. She earned a Master of Science in Nursing at Duke University, an Acute Care Nurse Practitioner certification at the University of Michigan and is currently enrolled in the DNP program at the Duke University School of Nursing. Ms. McDevitt provides comprehensive care to both inpatients and outpatients for the Pulmonary Hypertension Program, and she leads efforts in ongoing quality improvement and database research projects. She also serves on the Pulmonary Hypertension Professional Network (PHPN) Executive Committee for the Pulmonary Hypertension Association, including in her current role as PHPN 2021 Symposium Chair. She has numerous publications, has spoken at local and national conferences and is a sub-investigator for multiple PH clinical trials. She is an active member of the American Thoracic Society and the International Society of Heart and Lung Transplantation and serves on the Board of Directors for her local chapter of Sigma Theta Tau.
Speaker Disclosures
Martha Kingman, FNP-C, DNP, discloses relationships with the following companies:
- Actelion Pharmaceuticals, US, Inc., Janssen Pharmaceutical Company of Johnson & Johnson: Honoraria and speakers bureau for PH.
- Bayer: Speakers bureau for PH.
- United Therapeutics: speakers’ bureau for pulmonary hypertension.
Susanne E. McDevitt, MSN, ACNP-BC, has received consulting fees for PH from the following companies:
- Acceleron Pharma.
- Bayer.
- Janssen.
- United Therapeutics.